Polar Asset Management Partners Inc. Has $31.99 Million Holdings in Insulet Corporation $PODD

Key Points

• Polar Asset Management Partners Inc. has reduced its stake in Insulet Corporation by 44%, now holding approximately $31.99 million in shares.
• Insulet's recent quarterly earnings report showed an EPS of $1.17, surpassing analysts' estimates of $0.92, with revenues up 32.9% year-over-year.
• The stock currently has a consensus rating of "Moderate Buy" from analysts, with an average target price of $332.71.

Polar Asset Management Partners Inc. lessened its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 44.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,804 shares of the medical instruments supplier's stock after selling 95,838 shares during the period. Insulet comprises 0.7% of Polar Asset Management Partners Inc.'s holdings, making the stock its 26th largest position. Polar Asset Management Partners Inc. owned approximately 0.17% of Insulet worth $31,987,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Nissay Asset Management Corp Japan ADV increased its holdings in Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock worth $2,222,000 after purchasing an additional 48 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 64 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Insulet by 2.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,909 shares of the medical instruments supplier's stock worth $5,228,000 after purchasing an additional 440 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in Insulet by 2.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,635 shares of the medical instruments supplier's stock worth $955,000 after purchasing an additional 73 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Insulet during the 1st quarter worth about $24,478,000.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PODD. Canaccord Genuity Group increased their target price on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Wells Fargo & Company increased their target price on Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Citigroup restated a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $332.71.

Insulet Stock Performance

NASDAQ:PODD traded up $1.96 during mid-day trading on Friday, hitting $348.43. The stock had a trading volume of 498,473 shares, compared to its average volume of 554,308. Insulet Corporation has a twelve month low of $211.27 and a twelve month high of $350.00. The stock has a market cap of $24.53 billion, a price-to-earnings ratio of 105.91, a PEG ratio of 2.92 and a beta of 1.36. The company's 50 day simple moving average is $307.55 and its 200 day simple moving average is $289.87. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same period last year, the business posted $0.55 EPS. Insulet's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.